Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06310967
Other study ID # IG3018-23-02-01
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2024
Est. completion date June 2025

Study information

Verified date March 2024
Source Intelligem Therapeutics Australia Pty Ltd.
Contact Feng Yan
Phone +86 18612826692
Email yan.feng@intelligemtx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.


Description:

The study has two parts: Part 1 is a randomized, double-blind, placebo-controlled, dose escalation study in hyperuricemia subjects without CKD. Initiation Dose shall be at 0.25 g tablets (Cohort A) and doses are escalated to 0.5 g (Cohort B) and then to 1.0 g (Cohort C) in a planned manner. Part 2 is an open-label, proof of concept study involving hyperuricemia subjects with advanced predialysis CKD (Stage 3a, Stage 3b and Stage 4), and treated with two doses [0.5 g BID IG3018 (Cohort D) and 1.0 g BID IG3018 (Cohort E)].


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 46
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: For Part 1 and Part 2: Subjects must meet all the following criteria to be included in the study: 1. Male or female, aged 18 to 75 years (both inclusive). 2. According to the investigator's judgment, eGFR must be met as: Part 1 only, subjects without CKD and have eGFR = 60 mL/minute/1.73 m2 at screening phase; Part 2 only, subjects with CKD (Stage 3a, 3b and Stage 4) have eGFR=15 and <60 mL/minute/1.73 m2 at screening phase. 3. The serum uric acid level for subjects need to meet any of the following: For subjects already on ULT within 2 weeks prior to the screening visit, the serum uric acid would be measured during the screening visit/phase, and then at the end of the run-in phase, prior to confirming their eligibility. Subjects with ULT within 2 weeks before screening has fasting serum uric acid = 0.48 mmol/L at the end of run-in phase. For subjects without ULT in 2 weeks prior to screening visit,the serum uric acid should be measured twice on 2 different days (at least 24 hours apart) prior to confirming their eligibility. Subjects without ULT within 2 weeks before screening has fasting serum uric acid = 0.48 mmol/L at screening phase. 4. Body Mass Index (BMI) = 18 and = 35 kg/m2 (both inclusive) at screening. 5. Female subjects of child-bearing potential must agree to use highly effective contraceptive methods and must abstain from egg collection or donation from the screening phase to 90 days after the last dose of the study drug. And the male partner of a female subject also needs to agree to use highly effective method of birth control during this phase (Appendix 1). 6. Male subjects considered fertile must agree to not donate sperm, and take effective contraceptive methods from the screening phase to 90 days after the last dose of the study drug. And the female partner of male subjects also needs to agree to use a highly effective method of female contraception during this phase (Appendix 1). 7. Able to understand and give signed written informed consent form and willing to comply with all study procedures. Exclusion Criteria: For Part 1 and Part 2: Subjects who meet any of the following criteria will be excluded from the study: 1. Prior uricase therapy or exposure to recombinant uricase, such as Rasburicase or Pegloticase. 2. Subject has acute gout flares requiring treatment within 3 months prior to or during Screening. 3. Major surgery within 3 months prior to the first administration. 4. History of malignant tumors within 6 months prior to screening. 5. Subject within the last 3 months has: myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemia attack. 6. Subject who are on taking any other urate-lowering medication (allopurinol, febuxostat, probenecid and benzbromarone) and cannot stop during the study periods included in the run-in phase. 7. Subject with underlying medical conditions requiring changes or introduction of drugs that have the potential impact on the serum uric acid levels (e.g., salicylic acids, diuretics, angiotensin receptor blockers, etc.) within at least 1 month prior the screening phase. 8. History of gastrointestinal (GI) surgery, including gastric sleeve, colostomy/ enterostomy, Roux-en-Y or gastric banding (unless gastric band removed for a minimum of 12 months prior to Screening. 9. History of GI diseases, including gastrointestinal bleeding moderate to severe gastrointestinal dysfunction, moderate to severe chronic constipation for a minimum of 3 months prior to screening, or newly diagnosed peptic or duodenal ulcer diseases within 4 weeks prior to screening. 10. Inability to swallow oral medications. 11. Received treatment with or exposure to an Investigational drug or device within 30 days of signing informed consent. 12. Subject with one of positive results of HIV virus, or positive hepatitis B virus surface antigen (HBsAg) and the number of copies of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) = 500 IU/mL (or 2500 copies, or the lower limit of the positive detection value of the study site) at screening, or HBsAg (-), hepatitis B core antibody (HBcAb) (+) and the number of copies of HBV DNA = 500 IU/mL (or 2500 copies, or the lower limit of the positive detection value of the study site) after treatment of HBV infection, or positive hepatitis C antibody (HCV-Ab), and hepatitis C virus (HCV) ribonucleic acid (RNA) = ULN of the study site during Screening phase. 13. History of alcohol abuse, or subjects who consumed alcohol within 48 h before the first administration or did not agree to stop using alcohol products during the study. 14. Subject who has previously been diagnosed with the following diseases and has not been able to control them after medication therapy or other treatment. Uncontrolled is defined as hypertension: msSBP = 180mmHg and/or msDBP = 110mmHg; or Diabetes mellitus: HbA1c = 9% at screening. 15. Subject with secondary hyperuricemia caused by tumor, hematological system diseases, drugs, etc. except for chronic kidney disease; or hereditary hyperuricemia at screening. 16. Subjects undergoing kidney transplantation or planning to undergo kidney transplantation at screening. 17. History of serious hypersensitivity reaction to a known ingredient of IG3018 tablet judged by the investigator. 18. Subject who is considered unsuitable for participating in the study in the opinion of the investigator judgment.

Study Design


Intervention

Drug:
IG3018
Oral administration
Other:
Placebo matching IG3018
Oral administration

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Intelligem Therapeutics Australia Pty Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Assessments (Part 1 and Part 2) Safety as assessed by incidence of reported adverse events, clinically significant changes in vital signs, physical examination, laboratory tests, 12-lead ECG.
Safety as assessed by incidence of AEs by using the Common Terminology Criteria for Adverse Events, Version 5 (CTCAEv5).
Baseline through study completion at up to 46 days
Primary The proportions of change from baseline in serum uric acid to normal level (= 0.36 mmol/L) (Part 1 and Part 2) The proportions of change from baseline in serum uric acid to normal level (= 0.36 mmol/L) following 4 weeks treatment with IG3018 in each dose. 4 weeks
Secondary The proportions of change from baseline in serum uric acid to = 0.30 mmol/L and = 0.24 mmol/L respectively (Part 1 and Part 2) The proportions of change from baseline in serum uric acid to = 0.30 mmol/L and = 0.24 mmol/L respectively, following 4 weeks treatment with IG3018 in each dose. 4 weeks
Secondary The actual change of serum uric acid (Part 1 and Part 2) The actual change of serum uric acid from baseline to the end of 1, 2, 3, and 4 weeks of each treatment group. 4 weeks
Secondary The percentage change of serum uric acid (Part 1 and Part 2) The percentage change of serum uric acid from baseline to the end of 1, 2, 3, and 4 weeks of each treatment group. 4 weeks
Secondary Gouty Attacks (Part 1 and Part 2) Incidence of reported gouty attacks during the study period. Baseline through study completion at up to 46 days
Secondary Urinary Albumin/Creatinine Ration (U-ACR) (Part 2 only) The change in Urinary Albumin/Creatinine ration (U-ACR) during the study period. Baseline through study completion at up to 43 days
Secondary Ae of IG3018 (Part 1 only) Urine Accumulative excretion (Ae) of IG3018 32 days
Secondary Cmax of IG3018 (Part 1 only) Maximum observed plasma concentration of IG3018 46 days
Secondary Tmax of IG3018 (Part 1 only) Time to reach maximum plasma concentration of IG3018 46 days
Secondary T1/2 of IG3018 (Part 1 only) Terminal half-life of IG3018 46 days
See also
  Status Clinical Trial Phase
Recruiting NCT05434858 - Imagery as Biomarker of Gout N/A
Completed NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Phase 1
Recruiting NCT05504083 - Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients Phase 2
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Completed NCT00288158 - Primary Prevention of Hypertension in Obese Adolescents Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT04236219 - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Recruiting NCT06084585 - The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Not yet recruiting NCT04586803 - Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers Phase 1
Not yet recruiting NCT02944214 - Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients N/A
Completed NCT02959918 - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid Phase 2
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2
Active, not recruiting NCT01021241 - Safety and Efficacy Study of Intravenous Uricase-PEG 20 Phase 1
Completed NCT00756964 - Lowering Serum Uric Acid to Prevent Acute Kidney Injury Phase 2
Terminated NCT00607152 - Rasburicase (Fasturtec) Registration Trial Phase 3